Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04537156 | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | active not recruiting | Phase 3 | 9,327 | Xiamen UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT02333435 | Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life(RCT-EPA) | active not recruiting | Phase 2 | 130 | CHU de Quebec-Universite LavalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 3 | 445 | AkesoINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy(BladderSpar) | active not recruiting | Phase 2 | 79 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03837821 | (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer(CLONEVO) | active not recruiting | Early Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03912883 | Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting(TAPG) | active not recruiting | — | 3,350 | Queen Mary University of LondonOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT02339701 | Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer | active not recruiting | N/A | 68 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT04386746 | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer(GEMDOCE) | active not recruiting | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05924217 | Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France(GYDECAT) | active not recruiting | — | 300 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06733337 | A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer. | active not recruiting | — | 1 | PfizerINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06132945 | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | active not recruiting | Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02735252 | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | active not recruiting | N/A | 156 | University of California, San FranciscoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04922307 | Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer(RESTRICT) | active not recruiting | N/A | 240 | Vanderbilt University Medical CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02420847 | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 57 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04349501 | Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)(ProsRSI) | active not recruiting | N/A | 100 | University of California, San DiegoOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT06127836 | Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer | active not recruiting | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT06479187 | PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer | active not recruiting | Phase 4 | 20 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT01223248 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | active not recruiting | Phase 3 | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Nov 4, 2025 | clinicaltrials |
| NCT05100472 | A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02346747 | A Trial of Vigil for Participants With Ovarian Cancer(VITAL) | active not recruiting | Phase 2 | 92 | Gradalis, Inc.INDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05456685 | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 125 | AbbVieINDUSTRY | 6 | Oct 28, 2025 | clinicaltrials |
| NCT04574635 | Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer | active not recruiting | — | 18 | Mayo ClinicOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05779943 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | active not recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT01794403 | Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer(HEAT) | active not recruiting | N/A | 161 | University of MiamiOTHER | 3 | Oct 24, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT06436248 | Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer(PROMISE) | active not recruiting | — | 24 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06084416 | A Study of Sovilnesib in Subjects With Ovarian Cancer | active not recruiting | Phase 1 | 120 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | active not recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04106414 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | active not recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06577220 | Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement | active not recruiting | N/A | 111 | Baylor College of MedicineOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT01514669 | Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer | active not recruiting | — | 75 | University of ArkansasOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05540392 | An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues | active not recruiting | Phase 1 / Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05540782 | A Study of Cognitive Health in Survivors of Prostate Cancer | active not recruiting | — | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02917798 | Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes | active not recruiting | — | 1,047 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07207902 | Surveillance or Focal Therapy(SOFT) | active not recruiting | N/A | 400 | Kaiser PermanenteOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02828618 | Trial on Radical Upfront Surgery in Advanced Ovarian Cancer(TRUST) | active not recruiting | N/A | 797 | AGO Study GroupOTHER | 8 | Oct 3, 2025 | clinicaltrials |
| NCT03438708 | Prior Axitinib as a Determinant of Outcome of Renal Surgery(PADRES) | active not recruiting | Phase 2 | 22 | University of California, San DiegoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04250766 | Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors (BIOPSAR)(BIOPSAR) | active not recruiting | N/A | 19 | Institut BergoniéOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer(NESCIO) | active not recruiting | Phase 2 | 69 | The Netherlands Cancer InstituteOTHER | 2 | Sep 30, 2025 | clinicaltrials |
| NCT00261456 | The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer | active not recruiting | — | 3,500 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT03158922 | The BARCODE 1 Pilot Study(BARCODE1Pilot) | active not recruiting | — | 329 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2025source: clinicaltrials